Literature DB >> 16877907

Respiratory outcome of midface advancement with distraction: a comparison between Le Fort III and frontofacial monobloc.

Irene Mathijssen1, Eric Arnaud, Daniel Marchac, Etienne Mireau, Marie-Paule Morisseau-Durand, Philippe Guérin, Dominique Renier.   

Abstract

Upper airway stenosis in patients with faciocraniosynostosis is very common and often severe. Midface advancement, either with a Le Fort III or concomitantly to a monobloc frontofacial advancement, may prevent a tracheotomy or result in its ablation. The amelioration of respiratory function appears to be much better if the midface advancement is combined with distraction osteogenesis, although large studies with long-term follow-up are rare. In this study, we reviewed the respiratory outcome between Le Fort III with distraction and monobloc advancement with distraction in 54 faciocraniosynostotic patients. Early respiratory results of both procedures were very good and stable at long-term follow-up. The choice between a Le Fort III and a monobloc procedure is made on the basis of presenting morphology, previous surgery, and age. Both can be expected to give a long-lasting improvement of upper airway obstruction.

Entities:  

Mesh:

Year:  2006        PMID: 16877907     DOI: 10.1097/00001665-200607000-00006

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  2 in total

1.  Long-term surgical cure of severe obstructive sleep apnea in an adult patient with craniofacial dysostosis (Crouzon's syndrome): a case report and literature review.

Authors:  Manolis Papagrigorakis; Georgios A Vilos; Charalabos Apostolidis; Euphemia Daskalopoulou; Manolis Vlachogiannis
Journal:  Sleep Breath       Date:  2010-08-26       Impact factor: 2.816

2.  Advances in the Treatment of Syndromic Midface Hypoplasia Using Monobloc and Facial Bipartition Distraction Osteogenesis.

Authors:  Anand R Kumar; Derek Steinbacher
Journal:  Semin Plast Surg       Date:  2014-11       Impact factor: 2.314

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.